DUBLIN--(BUSINESS WIRE)--The "Global Guillain-Barré Syndrome Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The Guillain-Barré syndrome treatment market is projected to register a CAGR of more than 5% by 2023.
The trend of strategic alliances to help market grow at a flourishing rate. Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barré syndrome. These alliances will enhance the R&D activities of new drugs for the management of Guillain-Barré syndrome.
Immunoglobulins are the first line treatment of Guillain-Barré syndrome. The recent approvals of novel immunoglobulins from regulatory bodies are expected to propel the growth of the global Guillain-Barré syndrome treatment market during the forecast period.
Currently there is no cure for Guillain-Barré syndrome. The goal of the available treatments is to provide relief from the symptoms of disease. Although the intravenous immunoglobin therapy is more convenient and widely available, it has certain side effects. Hence, some physicians are strongly inclined toward other available plasma exchange procedures for the treatment of Guillain-Barré syndrome.
Key Players
- CSL
- Grifols
- Octapharma
- Shire
- Kedrion
Topics Covered
1. Executive Summary
2. Scope of the Report
3. Market Landscape
4. Market Sizing
5. Five Forces Analysis
6. Market Segmentation by Product
7. Customer Landscape
8. Geographic Landscape
9. Decision Framework
10. Drivers and Challenges
11. Trends
12. Vendor Landscape
13. Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/5d6fw5/global?w=4
